ORIC Pharmaceuticals Q2 2025 Report Overview [Executive Summary](index=1&type=section&id=ORIC%C2%AE%20Pharmaceuticals%20Reports%20Second%20Quarter%202025%20Financial%20Results%20and%20Operational%20Updates) ORIC Pharmaceuticals reports positive ORIC-944 clinical data, strengthened cash, and revised operational plans extending cash runway to late 2028 - The Phase 1b trial of ORIC-944 combined with AR inhibitors for mCRPC patients reported potentially best-in-class clinical efficacy and safety data[1](index=1&type=chunk) - The company's cash position was strengthened by **$244 million** in proceeds from a **$125 million** private placement and a **$119 million** ATM offering, concluding the use of the ATM facility[1](index=1&type=chunk) - Operational plans were revised to significantly reduce investment in discovery research, preparing for potential registrational trials of ORIC-944 and enozertinib (ORIC-114) in 2026[1](index=1&type=chunk)[2](index=2&type=chunk) - With revised operational plans and additional financing, cash and investments are projected to support operations into **late 2028** (previously late 2027), covering primary endpoint data readouts for the first Phase 3 trials of ORIC-944 and enozertinib[1](index=1&type=chunk)[2](index=2&type=chunk) [Second Quarter 2025 and Other Recent Highlights](index=1&type=section&id=Second%20Quarter%202025%20and%20Other%20Recent%20Highlights) The company detailed progress on key clinical programs, completed financing, prioritized its pipeline, and extended its cash runway [ORIC-944 Clinical and Preclinical Data](index=1&type=section&id=ORIC-944%3A%20a%20potent%20and%20selective%20allosteric%20inhibitor%20of%20PRC2) ORIC-944 Phase 1b trial data in mCRPC patients showed promising efficacy and safety, supported by synergistic preclinical activity - The Phase 1b trial of ORIC-944 combined with AR inhibitors for metastatic castration-resistant prostate cancer (mCRPC) reported preliminary efficacy and safety data: * **PSA50 response rate reached 59%** (47% confirmed), **PSA90 response rate reached 24%** (all confirmed)[3](index=3&type=chunk)[6](index=6&type=chunk) * PSA responses were observed across all ORIC-944 dose levels, with similar response rates when combined with apalutamide and darolutamide[3](index=3&type=chunk)[6](index=6&type=chunk) * Both combination regimens demonstrated safety compatible with long-term administration, with the vast majority of adverse events being Grade 1 or 2, and no Grade 4 events[3](index=3&type=chunk)[6](index=6&type=chunk) - Preclinical data for ORIC-944 presented at the 2025 AACR Annual Meeting showed synergistic activity and improved progression-free survival in both castration-resistant and castration-sensitive prostate cancer models when combined with androgen receptor pathway inhibitors[6](index=6&type=chunk) [Enozertinib (ORIC-114) Updates](index=2&type=section&id=Enozertinib%20(formerly%20ORIC-114)%3A%20a%20brain%20penetrant%20inhibitor%20that%20selectively%20targets%20EGFR%20exon%2020%2C%20HER2%20exon%2020%20and%20EGFR%20atypical%20mutations) Enozertinib (ORIC-114) continues patient enrollment in Phase 1b NSCLC trials and has received its non-proprietary name - Continued enrollment of advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations, including those with or without symptomatic but untreated CNS metastases, in the enozertinib monotherapy Phase 1b trial[6](index=6&type=chunk) - Continued enrollment of 1L NSCLC patients with EGFR exon 20 mutations in the enozertinib combined with subcutaneous (SC) amivantamab Phase 1b trial[6](index=6&type=chunk) - The World Health Organization International Nonproprietary Names (INN) Expert Committee has approved "enozertinib" as the nonproprietary (generic) name for ORIC-114[6](index=6&type=chunk) [Corporate Highlights](index=2&type=section&id=Corporate%20Highlights%3A) The company completed financing, strategically prioritized its pipeline, reduced its workforce, and extended its cash runway - Completed a **$125 million** private placement and issued **$119 million** from an at-the-market (ATM) facility, with the company concluding the use of the ATM facility given current cash and investment status, with no anticipated future use[6](index=6&type=chunk) - Announced strategic pipeline prioritization, focusing operational and financial resources on advancing two key clinical programs, ORIC-944 and enozertinib, leading to the dissolution of the discovery research team and a **20% workforce reduction**[6](index=6&type=chunk) - Anticipates approximately **$1.9 million** in one-time charges in Q3, primarily related to termination benefits, including severance and health-related benefits[6](index=6&type=chunk) - Due to strategic pipeline prioritization, the cash runway is projected to support revised operational plans into **late 2028** (previously late 2027), extending beyond the primary endpoint data readouts for the first Phase 3 trials of ORIC-944 and enozertinib[6](index=6&type=chunk) [Anticipated Program Milestones](index=3&type=section&id=Anticipated%20Program%20Milestones%3A) ORIC Pharmaceuticals outlined key data milestones for ORIC-944 and enozertinib from late 2025 through mid-2026 - **ORIC-944 (mCRPC) Milestones:** * **Late 2025:** Updated Phase 1b data with AR inhibitor combination[10](index=10&type=chunk) * **Q1 2026:** Dose optimization data with AR inhibitor combination[10](index=10&type=chunk) - **Enozertinib (ORIC-114) (NSCLC) Milestones:** * **Late 2025:** 1L EGFR exon 20, 2L EGFR exon 20, 2L+ HER2 exon 20, and 2L+ EGFR atypical data[10](index=10&type=chunk) * **Mid-2026:** 1L EGFR atypical data and 1L EGFR exon 20 with SC amivantamab combination data[10](index=10&type=chunk) [Second Quarter 2025 Financial Results](index=3&type=section&id=Second%20Quarter%202025%20Financial%20Results) The company reported its financial position, cash, investments, and year-over-year changes in R&D and G&A expenses for Q2 2025 Cash, Cash Equivalents, and Investments | Metric | As of June 30, 2025 | As of June 30, 2025 (Proforma) | | :-------------------------------- | :------------------ | :------------------------------ | | Cash, cash equivalents and investments | $327.7 million | $436.4 million | | Proceeds from private placement (May 2025) | $125.0 million | N/A | | Proceeds from ATM offering (Q2 2025) | $8.9 million | N/A | | Net proceeds from ATM (post Q2 2025) | N/A | $108.7 million | | Expected cash runway | Into 2H 2028 | Into 2H 2028 | Research and Development (R&D) Expenses | Period | 2025 (in millions) | 2024 (in millions) | Change (YoY) | | :-------------------- | :----------------- | :----------------- | :----------- | | Three months ended June 30 | $30.5 | $28.9 | +$1.6 million | | Six months ended June 30 | $55.2 | $50.9 | +$4.3 million | - The increase in R&D expenses was due to higher personnel costs (including non-cash stock-based compensation) and increased costs for advancing the enozertinib program, partially offset by reduced costs from terminated programs[10](index=10&type=chunk) General and Administrative (G&A) Expenses | Period | 2025 (in millions) | 2024 (in millions) | Change (YoY) | | :-------------------- | :----------------- | :----------------- | :----------- | | Three months ended June 30 | $8.5 | $7.1 | +$1.4 million | | Six months ended June 30 | $16.6 | $14.1 | +$2.5 million | - The increase in G&A expenses was primarily due to higher personnel costs and professional service fees, including additional non-cash stock-based compensation[10](index=10&type=chunk) [Company Information & Disclosures](index=3&type=section&id=Company%20Information%20%26%20Disclosures) [About ORIC Pharmaceuticals, Inc.](index=3&type=section&id=About%20ORIC%20Pharmaceuticals%2C%20Inc.) ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming cancer resistance with key candidates ORIC-944 and enozertinib - A clinical-stage biopharmaceutical company dedicated to improving patient lives by overcoming cancer resistance[9](index=9&type=chunk) - Clinical-stage lead product candidates include: * **ORIC-944:** An allosteric inhibitor of PRC2 (EED subunit) for prostate cancer[9](index=9&type=chunk)[11](index=11&type=chunk) * **Enozertinib (ORIC-114):** A brain-penetrant inhibitor selectively targeting EGFR exon 20, HER2 exon 20, and EGFR atypical mutations for various genetically defined cancers[9](index=9&type=chunk)[11](index=11&type=chunk) [Cautionary Note Regarding Forward-Looking Statements](index=4&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This standard disclaimer informs readers that forward-looking statements are subject to risks and uncertainties, and actual results may differ materially - Statements in this press release that are not purely historical are forward-looking statements as defined by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934[12](index=12&type=chunk) - Forward-looking statements are based on ORIC's current expectations and involve assumptions that may not be realized or prove incorrect, with actual results potentially differing materially due to numerous risks and uncertainties[12](index=12&type=chunk) - Risks include those related to drug discovery, development, and commercialization; clinical trial results potentially differing from expectations; financing needs; regulatory developments; reliance on third parties; intellectual property; loss of key personnel; industry competition; and macroeconomic and market conditions[12](index=12&type=chunk) [Contact Information](index=5&type=section&id=Contact%3A) Provides contact information for investor and media inquiries - Contact: **Dominic Piscitelli**, Chief Financial Officer[14](index=14&type=chunk) - Email: dominic.piscitelli@oricpharma.com, info@oricpharma.com[14](index=14&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) [Condensed Balance Sheets](index=6&type=section&id=CONDENSED%20BALANCE%20SHEETS) Presents the company's financial position, assets, liabilities, and equity as of June 30, 2025, compared to December 31, 2024 Condensed Balance Sheets (in thousands of dollars) | Metric | June 30, 2025 (unaudited) | December 31, 2024 | | :------------------------------------ | :------------------------ | :------------------ | | **Assets** | | | | Cash, cash equivalents and short-term investments | $282,513 | $255,960 | | Prepaid expenses and other current assets | $8,611 | $6,290 | | Total current assets | $291,124 | $262,250 | | Long-term investments | $45,216 | — | | Property and equipment, net | $2,762 | $2,924 | | Other assets | $7,755 | $8,968 | | **Total assets** | **$346,857** | **$274,142** | | **Liabilities and Stockholders' Equity** | | | | Accounts payable | $3,130 | $1,548 | | Accrued liabilities | $14,920 | $23,298 | | Total current liabilities | $18,050 | $24,846 | | Other long-term liabilities | $4,812 | $6,174 | | **Total liabilities** | **$22,862** | **$31,020** | | Total stockholders' equity | $323,995 | $243,122 | | **Total liabilities and stockholders' equity** | **$346,857** | **$274,142** | [Statements of Operations and Comprehensive Loss](index=7&type=section&id=STATEMENTS%20OF%20OPERATIONS%20AND%20COMPREHENSIVE%20LOSS) Details the company's financial performance, operating expenses, loss, and net loss for the three and six months ended June 30, 2025 and 2024 Statements of Operations and Comprehensive Loss (in thousands of dollars, except per share amounts) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------------ | :------------------------------- | :------------------------------- | :------------------------------- | :------------------------------- | | Research and development | $30,549 | $28,940 | $55,189 | $50,900 | | General and administrative | $8,515 | $7,077 | $16,593 | $14,107 | | **Total operating expenses** | **$39,064** | **$36,017** | **$71,782** | **$65,007** | | Loss from operations | $(39,064) | $(36,017) | $(71,782) | $(65,007) | | Other income, net | $2,709 | $4,054 | $5,406 | $8,033 | | **Net loss** | **$(36,355)** | **$(31,963)** | **$(66,376)** | **$(56,974)** | | Unrealized loss on investments | $(22) | $(94) | $(192) | $(514) | | **Comprehensive loss** | **$(36,377)** | **$(32,057)** | **$(66,568)** | **$(57,488)** | | Net loss per share, basic and diluted | $(0.47) | $(0.45) | $(0.89) | $(0.83) | | Weighted-average shares outstanding, basic and diluted | 78,126,257 | 70,348,414 | 74,602,994 | 68,848,981 |

Core Insights - ORIC Pharmaceuticals reported promising clinical efficacy and safety data from the ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for treating metastatic castration-resistant prostate cancer (mCRPC) [1][5] - The company strengthened its cash position with $244 million in gross proceeds from a $125 million private placement and $119 million from at-the-market (ATM) issuances, extending its cash runway into the second half of 2028 [1][9] - ORIC has revised its operating plan to focus on advancing its lead clinical programs, ORIC-944 and enozertinib, while significantly reducing investment in discovery research [2][9] Financial Highlights - As of June 30, 2025, ORIC reported cash, cash equivalents, and investments totaling $327.7 million, which increased to $436.4 million after additional fundraising [9][15] - Research and development (R&D) expenses for Q2 2025 were $30.5 million, up from $28.9 million in Q2 2024, reflecting higher personnel costs and advancement of enozertinib [9][15] - General and administrative (G&A) expenses for Q2 2025 were $8.5 million, compared to $7.1 million in Q2 2024, primarily due to increased personnel costs and professional services [9][15] Clinical Development Updates - ORIC-944 demonstrated a 59% PSA50 response rate and a 24% PSA90 response rate in patients with mCRPC, indicating its potential as a best-in-class PRC2 inhibitor [5] - Enozertinib continues to enroll patients in a Phase 1b trial targeting advanced non-small cell lung cancer (NSCLC) with specific EGFR and HER2 mutations [4][10] - The company anticipates initiating registrational trials for ORIC-944 and enozertinib in 2026, with key data milestones expected in late 2025 and mid-2026 [7][9]

Core Viewpoint - Oric Pharmaceuticals, Inc. (ORIC) is showing potential for a bullish breakout as it has reached a key support level and experienced a "golden cross" in its moving averages [1][4]. Technical Analysis - A "golden cross" occurs when a short-term moving average (50-day) crosses above a long-term moving average (200-day), indicating a potential bullish trend [2]. - The formation of a golden cross involves three stages: a downtrend that bottoms out, a crossover of moving averages, and subsequent upward momentum in stock prices [3]. Performance Metrics - Over the past four weeks, ORIC's stock has increased by 15.3% [4]. - The company currently holds a 1 (Strong Buy) rating on the Zacks Rank, suggesting strong bullish sentiment [4]. - Earnings expectations have improved, with two upward revisions in estimates for the current quarter and no downward revisions, indicating positive investor sentiment [4]. Investment Outlook - The combination of favorable earnings estimate revisions and the technical "golden cross" suggests that investors should monitor ORIC for potential further gains [5].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Oric Pharmaceuticals, Inc. (ORIC) - ORIC currently holds a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Performance Metrics - Over the past week, ORIC shares increased by 4.75%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.88% [5] - In the last quarter, ORIC shares surged by 140.04%, and over the past year, they gained 19.27%, while the S&P 500 only increased by 19.67% and 12.87%, respectively [6] - The average 20-day trading volume for ORIC is 896,080 shares, indicating a bullish sentiment as the stock is rising with above-average volume [7] Earnings Outlook - In the past two months, three earnings estimates for ORIC have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$1.98 to -$1.74 [9] - For the next fiscal year, two estimates have also moved upwards, with no downward revisions during the same period [9] Conclusion - Given the positive performance metrics and earnings outlook, ORIC is positioned as a promising investment opportunity with a Momentum Score of B and a Zacks Rank of 2 (Buy) [11]

Core Viewpoint - Oric Pharmaceuticals, Inc. (ORIC) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Oric Pharmaceuticals reflects an optimistic earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, influencing their buying and selling actions, which subsequently affects stock prices [5]. Recent Performance of Oric Pharmaceuticals - For the fiscal year ending December 2025, Oric Pharmaceuticals is expected to earn -$1.75 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 15.7% over the past three months [9]. Zacks Rank System Overview - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - Oric Pharmaceuticals' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].

Core Viewpoint - Oric Pharmaceuticals, Inc. (ORIC) has seen a significant stock price increase of 57.1% over the past four weeks, closing at $9.22, with analysts suggesting a potential upside of 105% based on a mean price target of $18.9 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $4.04, indicating variability among analysts [2]. - The lowest price target is $12.00, suggesting a 30.2% increase from the current price, while the highest target is $25.00, indicating a potential surge of 171.2% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, two earnings estimates for ORIC have been revised upward, leading to a 7.8% increase in the Zacks Consensus Estimate [12]. - ORIC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction indicated by these targets appears to be a useful guide for potential price movement [14].

Company Overview - Oric Pharmaceuticals, Inc. (ORIC) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance expectations [4] Performance Metrics - Over the past week, ORIC shares have increased by 14.08%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 5.43% [6] - In a longer time frame, ORIC's monthly price change is 104.01%, significantly higher than the industry's 7.54% [6] - Over the last quarter, ORIC shares have risen by 28.76%, and over the past year, they are up 25.91%, while the S&P 500 has only moved 8.33% and 12.92%, respectively [7] Trading Volume - ORIC's average 20-day trading volume is 1,988,020 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, 5 earnings estimates for ORIC have been revised upwards, while only 1 has been revised downwards, leading to an increase in the consensus estimate from -$2.06 to -$1.75 [10] - For the next fiscal year, 3 estimates have moved upwards, with 1 downward revision during the same period [10] Conclusion - Given the strong performance metrics and positive earnings outlook, ORIC is positioned as a promising investment opportunity with a Momentum Score of A [12]

Summary of Oric Pharmaceuticals (ORIC) FY Conference Call Company Overview - **Company**: Oric Pharmaceuticals (ORIC) - **Industry**: Clinical stage oncology, focusing on small molecule treatments for solid tumors, specifically prostate cancer, lung cancer, and breast cancer [2][3] Key Programs and Pipeline - **ORIC-944**: An allosteric PRC2 inhibitor in combination with AR inhibitors for prostate cancer [3][4] - **ORC-114**: A brain-penetrant EGFR HER2 exon 20 inhibitor for non-small cell lung cancer mutations [4][63] Clinical Development and Data - **Upcoming Studies**: Plans to initiate two Phase III studies in 2026 for ORIC-944 and ORC-114 [4][88] - **Recent Data**: Initial data from a Phase 1b study showed a PSA 50 response of 47% and a PSA 90 response of 24% in combination with AR inhibitors, which is favorable compared to Pfizer's data [18][20] - **Safety Profile**: ORIC-944 demonstrated a lower incidence of treatment-related adverse events compared to Pfizer's PRC2 inhibitor, with a diarrhea rate of 53% and only one grade three event [19][20] Competitive Landscape - **Market Opportunity**: Prostate cancer represents a significant market with approximately 40,000 to 50,000 patients in metastatic CRPC annually [34] - **Comparison with Competitors**: ORIC-944 aims to differentiate itself from Pfizer's mebrometostat by having a longer half-life (20 hours vs. 2 hours) and a potentially better safety profile [12][33][34] - **Other Competitors**: Awareness of several other PRC2 inhibitors in development, including those from Novartis and various companies in China, which may not be optimized for prostate cancer [40][41] Future Expectations and Updates - **Next Updates**: Anticipated updates on ORIC-944 in the second half of 2025, with a focus on PSA response and safety [51][56] - **Phase III Study Timeline**: Expected to start the Phase III study for ORIC-944 in the first half of 2026 [57][88] Financial Position - **Recent Financing**: Raised $125 million in a PIPE financing, extending cash runway into the second half of 2027 [88] - **Cash Management**: The cash runway includes funding for both assets and assumes no strategic partnerships, covering all costs associated with the upcoming Phase III studies [88] Additional Insights - **Combination Studies**: ORIC-114 is being studied in combination with amivantamab, which may provide synergistic effects due to its unique mechanism of action [80][84] - **Patient Population**: ORIC's studies allow for patients with active metastases, which is a differentiating factor compared to other trials that have stringent inclusion criteria [67][72] This summary encapsulates the key points discussed during the conference call, highlighting Oric Pharmaceuticals' strategic focus, clinical advancements, competitive positioning, and financial outlook.

Summary of Oric Pharmaceuticals (ORIC) 2025 Conference Call Company Overview - **Company Name**: Oric Pharmaceuticals (ORIC) - **Focus**: Development of small molecule drugs targeting solid tumors, specifically in lung cancer, prostate cancer, and breast cancer [4][5] Key Programs - **ORIC-944**: A PRC2 inhibitor for prostate cancer, currently in combination studies with two androgen receptor inhibitors (apalutamide and darolutamide) [5][6] - **ORIC-114**: A brain-penetrant inhibitor targeting lung cancer populations, including EGFR exon 20, EGFR atypicals, and HER2 exon 20 [6] Clinical Data and Comparisons - **Prostate Cancer Data**: - ORIC-944 showed a confirmed PSA 50 response rate of 47% compared to Pfizer's mevremetostat at 34% [10][13] - Confirmed PSA 90 response rate for ORIC-944 was 24% versus Pfizer's 12% [11][13] - Safety profile of ORIC-944 demonstrated lower rates of gastrointestinal toxicity compared to Pfizer's drug [14][15] Safety and Efficacy - **Toxicity Comparison**: ORIC-944 exhibited significantly lower rates of GI toxicity and anemia compared to Pfizer's data, which reported high rates of diarrhea and dysgeusia [14][15] - **Dosing Strategy**: ORIC-944 has a longer half-life allowing for once-daily dosing, while Pfizer's drug requires twice-daily dosing [26][27] Future Development Plans - **Phase III Study**: Planned to start in the first half of 2026, focusing on both post-abiraterone and post-AR inhibitor populations [33][44] - **Data Updates**: Two additional data updates expected later in 2025, focusing on dose escalation and optimization [34][36] Market Position and Strategy - **Competitive Landscape**: ORIC aims to close the timeline gap with Pfizer, emphasizing that being a second entrant in a large market can still yield significant commercial opportunities [60][61] - **Partnerships**: Strong relationships with Janssen and Bayer for drug supply and insights into clinical development [51][52] Financial Position - **Cash Position**: As of March, ORIC reported a pro forma cash position of $349 million, providing a runway into the second half of 2027 [73] Additional Insights - **ctDNA as a Biomarker**: ORIC is exploring ctDNA as a potential better marker for long-term durability compared to PSA activity [40][41] - **Focus on Frontline Opportunities**: ORIC is prioritizing frontline strategies for ORIC-114, aiming for robust data in competitive populations [63][64] Conclusion - ORIC Pharmaceuticals is positioned to advance its clinical programs with promising early data, a strong financial position, and strategic partnerships, while navigating a competitive landscape in oncology.

Core Viewpoint - Oric Pharmaceuticals, Inc. (ORIC) has seen a significant stock price increase of 44.1% over the past four weeks, closing at $8.17, with analysts suggesting a potential upside to a mean price target of $18.90, indicating a 131.3% increase from the current price [1] Price Targets and Analyst Consensus - The average price target from analysts ranges from a low of $12 to a high of $25, with a standard deviation of $4.04, suggesting a potential increase of 46.9% to 206% from the current price level [2] - A low standard deviation indicates a strong agreement among analysts regarding the price targets, which can be a useful indicator for further research [2][9] Earnings Estimates and Market Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, five estimates for ORIC have increased, leading to a 12.6% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - ORIC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]